secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0000950170-25-106932
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics Q2 2025 net loss $6.1M; cash $29.8M; FDA decision on COYA 302 ALS IND by Aug 29
--------------------------------------------------------------------------------

- Net loss $6.1M vs $2.9M in Q2 2024; collaboration revenue fell to $0.2M from $3.4M.
- Cash and equivalents $29.8M as of June 30, 2025.
- R&D expenses $3.7M (down $0.9M YoY); G&A $2.9M (up $0.8M YoY).
- FDA decision on IND for COYA 302 in ALS expected by August 29, 2025; upon acceptance, DRL milestone payment of $8.4M.
- Additional catalysts: top-line data from FTD trial, IND for FTD by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000095017025106932/0000950170-25-106932-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000095017025106932/coya-20250812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-106932

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer